NCT04780568View on ClinicalTrials.gov

Osimertinib and Tegavivint As First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 18, 2022

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2029

Conditions
Metastatic Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC V8Stage IVA Lung Cancer AJCC V8Stage IVB Lung Cancer AJCC V8
Interventions
DRUG

Osimertinib

Given PO

DRUG

Tegavivint

Given IV

Trial Locations (1)

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
lead

Ohio State University Comprehensive Cancer Center

OTHER